The research is very clear that the biggest obstacle to boosting NAD+ levels is bioavailabilty.
We took the first step in solving that problem with our NMN and NAD+ powders and sublingual tablets.
Now we’ve taken an even bigger step with our advanced nanoliposome hydrogel featuring Control Release Kinetics designed for sublingual delivery.
LSG™ – combining the power of Liposomes & Sublingual delivery in advanced Gel technology
LSG™ nanoparticles are 20-40 nanometers – smaller than wavelengths of visible light – to maximize biological efficiency and precision performance. Smaller lipsomes penetrate the epithelium more readily, and are not filtered out by the liver as larger liposomes are.
This sublingual delivery system features Control Release Kinetics™, using sustained release liposomes to protect nutrients before release into systemic circulation with improved efficacy.
Our nanoparticulate Gel technology is formulated to improve active compound permeability across the epithelium, provide optimal solubilization and maximize systemic release kinetics.
Liposomes are vesicles comprised of phospholipid molecules – the same molecules that comprise cell membranes. Liposomal drug delivery systems have excellent biocompatibility, low toxicity and lack of immune system activation.
Phospholipid molecules consist of a hydrophilic phosphate head and two hydrophobic fatty acid tails. These features enable liposomes to be able to transport hydrophobic and hydrophilic compounds effectively. Due to low absorption and bioavailability rates of traditional oral dietary capsules, the encapsulation of hydrophilic and hydrophobic nutrients within liposomes allows the active ingredient to bypass the destructive elements of the gastric system.
Liposomes release drug molecules by membrane fusion. To release the protected molecules to a site of action, the lipid bilayer fuses with other bilayers such as the cell membrane, delivering the liposome contents directly into the cells and tissues intact.
Wikipedia: “When a chemical comes in contact with the mucous membrane beneath the tongue, it is absorbed. Because the connective tissue beneath the epithelium contains a profusion of capillaries, the substance then diffuses into them and enters the venous circulation. In contrast, substances absorbed in the stomach and intestines are subject to first-pass metabolism in the liver before entering the general circulation and typically have very poor bioavailability.”
The phospholipids in liposomes utilize the sublingual pathway to bring their payload directly into systemic circulation.
However, the quantity of liposomes delivered in liquid or spray is extremely limited and larger dosages are required, resulting in more of the product being swallowed.
The highly permeable sublingual entry site can be utilized for longer duration when administered in the form of our proprietary bioadhesive gel.
With a 0.1-0.7 mm thick mucus layer, the oral cavity is an effective route of administration for mucoadhesive dosages.
Our mucoadhesive gel is designed to adhere to biological tissues, prolong residence time and maintain an optimal release rate. LSG™ is designed to assure prolonged retention time by dynamically increasing the viscosity of the gel after application.
Controlled Release Kinetics™ within the hydrogel technology provide further advanced bioavailability and efficacy.
Bioadhesive Hydrogel – Innovative Liposomal Suspension
Our LSG™ technology provides controlled-release performance with liposomes suspended in a natural bioadhesive gel. The loaded hydrogel increases contact time to improve performance over liquid products where production of saliva induces swallowing rather than sublingual absorption.
The mucoadhesive gel in our LSG products is designed to avoid rapid clearance of nutrient nanoparticles and maintain a long-term concentration gradient at the mucosal surface to ensure the unidirectional diffusion, and provides unsurpassed bioavailability with higher systemic delivery of nutrients to systemic circulation.
Research on Liposomes
Liposomal Fisetin 1.6 to 27x more bioavailableThis study in mice found a 2.7-fold increase (in Cmax) with Liposomal Fisetin, with a dose 10 times lower than that of the free fisetin when given by IP. With IV, the Cmax of liposomal fisetin was 10, vs 6 for free fisetin.
Liposomal Vitamin B-12 formulas 3-5x more bioavailable than tablet.
- (i)Nanocelle 1000ug -28% – A nano liposomal formulation of B12sublingual spray with an average particle size of about 20 nm